Narjust Duma, Rafael Santana-Davila, Julian R Molina. Non-Small Cell Lung Cancer: Epidemiology, Screening, diagnosis, and Treatment[J]. Mayo Clin Proc 2019,94(8):1623–40.

Tetsuya MDTJC-H, Yang M-JA. Ullas Batra, Byoung-Chul Cho, Gerardo Cornelio, Tony Lim, Tony Mok, Kumar Prabhash, Thanyanan Reungwetwattana, Sheng-Xiang Ren, Navneet Singh, Shinichi Toyooka, Yi-Long Wu, Pan-Chyr Yang, Yasushi Yatabe. Expert Consensus recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia[J]. J Thorac Oncol. 2023;18(4):436–46.

Google Scholar 

Marina CG, Julien Mazieres, Martin Reck, Christos Chouaid, Helge Bischoff, Niels Reinmuth, Laura Cove-Smith, Talal Mansy,Diego Cortinovis, Maria RM. Angelo Delmonte, José Garcia Sánchez, Luis Enrique Chara Velarde, Reyes Bernabe, Luis Paz-Ares, Ignacio Diaz Perez, Nataliya Trunova,Kayhan Foroutanpour, Corinne Faivre Finn. Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial[J]. J Thorac Oncol, 2022,17(12):1415–1427.

Hideyuki S. Tatsuya Ohno, Kazuhiko Ogawa. Current status and future prospects of particle therapy (proton beam and heavy ion therapy) in Japan-in the special issue of the J Radiation Research[J] J Radiat Res 2023,64(Suppl 1):i1.https://doi.org/10.1093/jrr/rrad034.

Zihan Z. Bingjie Guan, Huang Xia, Rong Zheng, Benhua Xu. Particle radiotherapy in the era of radioimmunotherapy[J]. Cancer Lett 2023 567:21626810.1016/j.canlet.2023.216268.

Di Huang WY-YLTWY-Y. Ping Xia. Computed tomography-guided lung biopsy with rapid on-site evaluation for diagnosis of lung lesions: a meta-analysis[J]. J Cardiothorac Surg. 2023;18(1):122. https://doi.org/10.1186/s13019-023-02212-6.

Article  PubMed  PubMed Central  Google Scholar 

Lori M, Minasian, Ann O’Mara, Sandra AM. Clinician and patient reporting of symptomatic adverse events in Cancer clinical trials: using CTCAE and PRO-CTCAE® to provide two distinct and complementary Perspectives[J]. Patient Relat Outcome Meas. 2022;13:249–58.

Article  Google Scholar 

Olga Rodak, Manuel David Peris-Díaz, Mateusz Olbromski, Marzenna Podhorska-Okołów,Piotr Dzięgiel.Current Landscape of Non-small Cell Lung Cancer: Epidemiology, histological classification, targeted therapies, and Immunotherapy[J]. Cancers (Basel),2021,13(18):4705.https://doi.org/10.3390/cancers13184705.

Alessandra B. Giulia Pasello, Giuseppe De Luca, Alberto Bortolami, Manuel Zorzi,Federico Rea, Carlo Pinato,Antonella Dal Cin, Anna De Polo,Marco Schiavon, Andrea Zuin,Marco Marchetti, Giovanna Scroccaro, Vincenzo Baldo,Massimo Rugge, Valentina Guarneri, PierFranco Conte. Non-Small-Cell Lung Cancer: real-world Cost Consequence Analysis[J]. JCO Oncol Pract,2021,17(8):e1085–93.

Jiajia W. Zhenghong Lin. Non-Small Cell Lung Cancer targeted therapy: Drugs and mechanisms of Drug Resistance[J]. Int J Mol Sci 2022,23(23):15056.https://doi.org/10.3390/ijms232315056.

Tina C. Jared Fradette, Monika Pradhan, Don L Gibbons. Tumor Immunology and Immunotherapy of Non-small-cell Lung Cancer[J]. Cold Spring Harb Perspect Med,2022,12(5):a037895.https://doi.org/10.1101/cshperspect.a037895.

Soo-Ryum Yang, Anne M, Schultheis. Helena Yu, Diana Mandelker, Marc Ladanyi,Reinhard Büttner. Precision medicine in non-small cell Lung cancer: current applications and future directions[J]. Semin Cancer Biol. 2022;84:184–98.

Article  Google Scholar 

Sabine Semrau,Gunther Klautke, Rainer Fietkau.Baseline cardiopulmonary function as an Independent prognostic factor for survival of inoperable non-small-cell Lung cancer after concurrent chemoradiotherapy: a single-center analysis of 161 cases[J]. Int J Radiat Oncol Biol Phys, 2011,79(1):96–104.

John C. Astra Z.Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell Lung cancer[J]. Br J Cancer. 2020;123(1):10–7.

Google Scholar 

Li Z. Pingfan Shi,Chenge Qin, Wen Zhang,Shumeng Lin, Tiansheng Zheng, Ming Li, Lihong Fan. Nomogram predicting overall survival of stage IIIB non-small-cell Lung cancer patients based on the SEER database[J]. Clin Respir J. 2023. https://doi.org/10.1111/crj.13660.

Article  PubMed  PubMed Central  Google Scholar 

Cortiula F, Reymen B, Peters S, Van Mol P, Wauters E, Vansteenkiste J, De Ruysscher D. L E L.Hendriks Immunotherapy in unresectable stage III non-small-cell Lung cancer: state of the art and novel therapeutic approaches[J]. Ann Oncol 2022,33(9):893–908.

Yonglong JYCWXB, Li. Jinpeng Xu,Dunmin Zhuang,Lina Dong,Xiguang Liu. The Co-mutation of CDKN2A and PDCD1LG2 may be a predictor of Duvalizumab -Induced Cytokine Storm in Non-small-cell Lung Cancer: a Case Report[J]. Global J Pharm Pharm Sci. 2021;8(5):159–65.

Google Scholar 

Nan BKXHGMCMLZJCX, Zhang. Xiao Ding, Bing Xia,Lujun Zhao, Lijie Han,Jiancheng Li, Chen Hu,Luhua Wang. Real-world treatment patterns and clinical outcomes in EGFR-mutant locally advanced lung adenocarcinoma: a multi-center cohort study[J]. J Natl Cancer Cent 2023, 3(1):65–71.

Zhe Chen MM, Dominello. Michael,Joiner, Jay W Burmeister. Proton versus photon radiation therapy: a clinical review[J].Front Oncol, 2023,https://doi.org/10.3389/fonc.2023.1133909.

Sophia CK, Jay OL, Jason AE. Proton versus photon-based radiation therapy for Prostate cancer: emerging evidence and considerations in the era of value-based cancer care[J]. Prostate Cancer Prostatic Dis 2019,22(4):509–21.

Habash M. Bohorquez LC, Kyriakou E. Clinical and functional assays of radiosensitivity and radiation induced second cancer[J]. Cancer(Basel), 2017,9(11):E147.

Gandhi S. Chandna S.Radiation induced in flammatory cascad and its reverberating crosstalks as potential cause of post radiotherapy second malignancies[J]. Cancer Metastasis Rev. 2017;36(2):375–93.

Article  CAS  PubMed  Google Scholar 

Randall JB. Nima Sharifai, Benjamin Fischer-Valuck, Comron Hassanzadeh, Jeffrey Guzelian, John S A Chrisinger, Jeff M Michalski, Peter Oppelt,Brian C Baumann. Abscopal Effect Following Proton Beam Radiotherapy in a Patient With Inoperable Metastatic Retroperitoneal Sarcoma[J]. Front Oncol,2019,9:922.https://doi.org/10.3389/fonc.2019.00922.

Yoshitaka Matsumoto, Nobuyoshi Fukumitsu, Hitoshi Ishikawa, Kei Nakai,Hideyuki Sakurai. A Critical Review of Radiation Therapy: From Particle Beam Therapy (Proton, Carbon, and BNCT) to Beyond[J]. J Pers Med,2021,11(8):825. https://doi.org/10.3390/jpm11080825.

Gjyshi O. Zhongxing Liao. Proton therapy for locally advanced non-small cell Lung cancer[J]. Br J Radiol. 2020;93(1107):20190378. https://doi.org/10.1259/bjr.20190378.

Article  PubMed  PubMed Central  Google Scholar 

Sejpal S, Komaki R, Tsao A, Chang JY, Liao Z, Wei X, Allen PK, Lu C, Gillin M, Cox JD. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell Lung cancer[J]. Volume 117. Cancer; 2011. pp. 3004–13.

Toshiki O. Yoshiko Oshiro, Masashi Mizumoto, Haruko Numajiri, Hitoshi Ishikawa, Toshiyuki Okumura, Toshiyuki Terunuma,Takeji Sakae, Hideyuki Sakurai. Comparison of dose-volume histograms between proton beam and X-ray conformal radiotherapy for locally advanced non-small-cell Lung cancer[J]. J Radiat Res. 2015;56(1):128–33.

Article  Google Scholar 

Hwang E, Gaito,A France,A M Crellin S, Thwaites DI, Ahern V, Indelicato D, Timmermann B. E Smith.Outcomes of patients treated in the UK Proton Overseas Programme: non-central nervous system. Group[J] Clin Oncol. 2023;35(5):292–300.

Article  CAS  Google Scholar 

Simona Gaito, Giulia Marvaso, Ramon Ortiz, Adrian Crellin, Marianne C, Aznar,Daniel JI. Shermaine Pan,Gillian Whitfield, Filippo Alongi, Barbara Alicja Jereczek Fossa,Neil Burnet, Michelle P Li, Bethany Rothwell, Ed Smith, Rovel J Colaco. Proton Beam Therapy in the Oligometastatic/Oligorecurrent setting: is there a Role? A Literature Review[J].Cancers (Basel), 2023,15(9): 2489.

Gaito S, Burnet NG, Aznar MC, Marvaso G, Fossa BAJ, Crellin A, Indelicato D, Pan S, Colaco R, Rieu R, Smith E. Whitfield.Proton Beam Therapy in the reirradiation setting of Brain and Base of Skull Tumour. Recurrences[J] Clin Oncol. 2023;35(10):673–81.

Article  CAS  Google Scholar 

Gaito S, Aznar MC, Burnet NG, Crellin A, France A, Indelicato D, Kirkby KJ, Pan S, Whitfield G. E. Smith.Assessing equity of Access to Proton Beam Therapy: A literature Review[J] Clin Oncol 2023,35(9):e528–36.

Neil G, Burnet,Thomas MS, Gaito, Norman F, Kirkby, Adam H, Aitkenhead, Carmel N, Anandadas, Marianne C, Aznar, Lisa H, Barraclough, Gerben Borst,Frances C, Charlwood, Matthew Clarke, Rovel J, Colaco, Adrian M, Crellin, Noemie N, Defourney,Christina JH, Henthorn,Kirsten T, Hopkins I, Hwang, Sam E, Ingram,Karen P, Kirkby,Lip J, Lee W, Catherine A, McBain,Michael J, Merchant,David J, Noble, Shermaine Pan, James M, Price. Ganesh Radhakrishna, David Reboredo-Gil, Ahmed Salem, Srijith Sashidharan, Peter Sitch, Ed Smith, Edward Ak Smith, Michael J Taylor, David J Thomson, Nicola J Thorp, Tracy Sa Underwood, John W Warmenhoven, James P Wylie, Gillian Whitfield. Estimating the percentage of patients who might benefit from proton beam therapy instead of X-ray radiotherapy[J]. Br J Radiol, 2022,95(1133):20211175.

Hwang E, Burnet NG, Crellin AM, Ahern V, Thwaites DI, Gaito S, Chang YC, Smith E. Therapy[J] Clin Oncol. 2022;34(1):11–8. .A Novel Model and Infrastructure for Clinical Outcomes Data Collection and Their Systematic Evaluation for UK Patients Receiving Proton Beam.